-
Je něco špatně v tomto záznamu ?
Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril
F. Simko, O. Pechanova, K. Repova, S. Aziriova, K. Krajcirovicova, P. Celec, L. Tothova, S. Vrankova, L. Balazova, S. Zorad, M. Adamcova,
Jazyk angličtina Země Švýcarsko
Typ dokumentu srovnávací studie, časopisecké články
NLK
Free Medical Journals
od 2000
Freely Accessible Science Journals
od 2000
PubMed Central
od 2007
Europe PubMed Central
od 2007
ProQuest Central
od 2000-03-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2007-01-01
Health & Medicine (ProQuest)
od 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
PubMed
28757582
DOI
10.3390/ijms18081612
Knihovny.cz E-zdroje
- MeSH
- acetylcystein škodlivé účinky analogy a deriváty MeSH
- antihypertenziva aplikace a dávkování farmakologie MeSH
- fibróza MeSH
- hypertenze chemicky indukované farmakoterapie etiologie MeSH
- kaptopril aplikace a dávkování farmakologie MeSH
- krysa rodu rattus MeSH
- melatonin aplikace a dávkování farmakologie MeSH
- modely nemocí na zvířatech MeSH
- NG-nitroargininmethylester škodlivé účinky MeSH
- potkani Wistar MeSH
- remodelace komor účinky léků MeSH
- srdeční komory účinky léků patologie MeSH
- světlo škodlivé účinky MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
Lactacystin is a proteasome inhibitor that interferes with several factors involved in heart remodelling. The aim of this study was to investigate whether the chronic administration of lactacystin induces hypertension and heart remodelling and whether these changes can be modified by captopril or melatonin. In addition, the lactacystin-model was compared with NG-nitro-l-arginine-methyl ester (L-NAME)- and continuous light-induced hypertension. Six groups of three-month-old male Wistar rats (11 per group) were treated for six weeks as follows: control (vehicle), L-NAME (40 mg/kg/day), continuous light (24 h/day), lactacystin (5 mg/kg/day) alone, and lactacystin with captopril (100 mg/kg/day), or melatonin (10 mg/kg/day). Lactacystin treatment increased systolic blood pressure (SBP) and induced fibrosis of the left ventricle (LV), as observed in L-NAME-hypertension and continuous light-hypertension. LV weight and the cross-sectional area of the aorta were increased only in L-NAME-induced hypertension. The level of oxidative load was preserved or reduced in all three models of hypertension. Nitric oxide synthase (NOS) activity in the LV and kidney was unchanged in the lactacystin group. Nuclear factor-kappa B (NF-κB) protein expression in the LV was increased in all treated groups in the cytoplasm, however, in neither group in the nucleus. Although melatonin had no effect on SBP, only this indolamine (but not captopril) reduced the concentration of insoluble and total collagen in the LV and stimulated the NO-pathway in the lactacystin group. We conclude that chronic administration of lactacystin represents a novel model of hypertension with collagenous rebuilding of the LV, convenient for testing antihypertensive drugs or agents exerting a cardiovascular benefit beyond blood pressure reduction.
Department of Physiology Faculty of Medicine Charles University 50003 Hradec Kralove Czech Republic
Institute of Molecular Biomedicine Faculty of Medicine Comenius University 81108 Bratislava Slovakia
Institute of Normal and Pathological Physiology Slovak Academy of Sciences 81371 Bratislava Slovakia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024781
- 003
- CZ-PrNML
- 005
- 20231121102408.0
- 007
- ta
- 008
- 180709s2017 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms18081612 $2 doi
- 035 __
- $a (PubMed)28757582
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Simko, Fedor $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. fedor.simko@fmed.uniba.sk. 3rd Clinic of Internal Medicine, Faculty of Medicine, Comenius University, 83305 Bratislava, Slovakia. fedor.simko@fmed.uniba.sk. Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia. fedor.simko@fmed.uniba.sk.
- 245 10
- $a Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril / $c F. Simko, O. Pechanova, K. Repova, S. Aziriova, K. Krajcirovicova, P. Celec, L. Tothova, S. Vrankova, L. Balazova, S. Zorad, M. Adamcova,
- 520 9_
- $a Lactacystin is a proteasome inhibitor that interferes with several factors involved in heart remodelling. The aim of this study was to investigate whether the chronic administration of lactacystin induces hypertension and heart remodelling and whether these changes can be modified by captopril or melatonin. In addition, the lactacystin-model was compared with NG-nitro-l-arginine-methyl ester (L-NAME)- and continuous light-induced hypertension. Six groups of three-month-old male Wistar rats (11 per group) were treated for six weeks as follows: control (vehicle), L-NAME (40 mg/kg/day), continuous light (24 h/day), lactacystin (5 mg/kg/day) alone, and lactacystin with captopril (100 mg/kg/day), or melatonin (10 mg/kg/day). Lactacystin treatment increased systolic blood pressure (SBP) and induced fibrosis of the left ventricle (LV), as observed in L-NAME-hypertension and continuous light-hypertension. LV weight and the cross-sectional area of the aorta were increased only in L-NAME-induced hypertension. The level of oxidative load was preserved or reduced in all three models of hypertension. Nitric oxide synthase (NOS) activity in the LV and kidney was unchanged in the lactacystin group. Nuclear factor-kappa B (NF-κB) protein expression in the LV was increased in all treated groups in the cytoplasm, however, in neither group in the nucleus. Although melatonin had no effect on SBP, only this indolamine (but not captopril) reduced the concentration of insoluble and total collagen in the LV and stimulated the NO-pathway in the lactacystin group. We conclude that chronic administration of lactacystin represents a novel model of hypertension with collagenous rebuilding of the LV, convenient for testing antihypertensive drugs or agents exerting a cardiovascular benefit beyond blood pressure reduction.
- 650 _2
- $a acetylcystein $x škodlivé účinky $x analogy a deriváty $7 D000111
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antihypertenziva $x aplikace a dávkování $x farmakologie $7 D000959
- 650 _2
- $a kaptopril $x aplikace a dávkování $x farmakologie $7 D002216
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a fibróza $7 D005355
- 650 _2
- $a srdeční komory $x účinky léků $x patologie $7 D006352
- 650 _2
- $a hypertenze $x chemicky indukované $x farmakoterapie $x etiologie $7 D006973
- 650 _2
- $a světlo $x škodlivé účinky $7 D008027
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a melatonin $x aplikace a dávkování $x farmakologie $7 D008550
- 650 _2
- $a NG-nitroargininmethylester $x škodlivé účinky $7 D019331
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a remodelace komor $x účinky léků $7 D020257
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pechanova, Olga $u Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, 81371 Bratislava, Slovakia. olga.pechanova@savba.sk.
- 700 1_
- $a Repova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. repova.k@gmail.com.
- 700 1_
- $a Aziriova, Silvia $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. silvia.aziriova@gmail.com.
- 700 1_
- $a Krajcirovicova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. krikratina@gmail.com.
- 700 1_
- $a Celec, Peter $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. petercelec@gmail.com. Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia. petercelec@gmail.com.
- 700 1_
- $a Tothova, Lubomira $u Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia. tothova.lubomira@gmail.com.
- 700 1_
- $a Vrankova, Stanislava $u Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, 81371 Bratislava, Slovakia. stanislava.vrankova@savba.sk.
- 700 1_
- $a Balazova, Lucia $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia. balazova.luc@gmail.com.
- 700 1_
- $a Zorad, Štefan, $d 1956- $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia. Stefan.Zorad@savba.sk. $7 xx0310348
- 700 1_
- $a Adamcova, Michaela $u Department of Physiology, Faculty of Medicine, Charles University, 50003 Hradec Kralove, Czech Republic. adamcova@lfhk.cuni.cz.
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 18, č. 8 (2017)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28757582 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20231121102405 $b ABA008
- 999 __
- $a ok $b bmc $g 1316912 $s 1021702
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 18 $c 8 $e 20170725 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- LZP __
- $a Pubmed-20180709